PI Health Sciences Financial Overview

Outlook remains positive...on path to deliver guided growth for FY24 Pi Inspired by Science Domestic: Focus on portfolio diversification with high quality revenue CSM Export: Technology focused approach to drive incremental business Health Sciences: Building a differentiated play in Pharma CRDMO space Monsoon deficit in south and low reservoir levels Elevated inventory levels in the industry for row crop Agchem products and price pressure from generics to continue Integrated crop solution approach with focus on quality of revenue and efficient NWC management Continued scale up in demand of the newly commercialised products: to drive growth in next quarters Solid R&D pipeline of diversified portfolio of Agchem, electronic, imaging and other specialty chemicals - 4 to 5 products to be commercialized every year - ~30% from non-Agchem Capacity expansion in line with plan - to commission 2 plants in next 1-year Operating model, functional and IT integration of acquired companies nearing completion New business development efforts intensified Build-up of Hyderabad research center and staffing at full swing; soon getting commissioned Capex committed for upgrade of facilities and building cutting-edge capabilities at Lodi and Jaipur facilities Progressing on strategic initiatives in line with plan Strong pipeline of Biologicals and Biostimulant products at different stages of development • Actively evaluating a few inorganic growth opportunities Promising R&D leads progressing towards development phase 13

View entire presentation